| 12/06/25 | GSK | 11:00:00 | 12 Jun 2025 | | GSK | Director/PDMR Shareholding | GSK plc | PRN |
| 13/10/22 | GSK | 08:26:25 | 13 Oct 2022 | | GSK | Director/PDMR Shareholding | GSK PLC | RNS |
| 13/10/22 | GSK | 07:00:01 | 13 Oct 2022 | | GSK | Efficacy results for GSK’s older adult RSV vaccine | GSK PLC | RNS |
| 12/10/22 | GSK | 11:42:12 | 12 Oct 2022 | | GSK | Director/PDMR Shareholding | GSK PLC | RNS |
| 10/10/22 | GSK | 07:00:04 | 10 Oct 2022 | | GSK | US FDA approves Boostrix maternal immunisation | GSK PLC | RNS |
| 07/10/22 | GSK | 16:38:27 | 7 Oct 2022 | | GSK | Director/PDMR Shareholding | GSK PLC | RNS |
| 07/10/22 | GSK | 16:24:24 | 7 Oct 2022 | | GSK | Director/PDMR Shareholding | GSK PLC | RNS |
| 03/10/22 | GSK | 10:10:05 | 3 Oct 2022 | | GSK | Total Voting Rights | GSK PLC | RNS |
| 30/09/22 | GSK | 17:21:33 | 30 Sept 2022 | | GSK | Director/PDMR Shareholding | GSK PLC | RNS |
| 26/09/22 | GSK | 17:09:56 | 26 Sept 2022 | | GSK | Director/PDMR Shareholding | GSK PLC | RNS |
| 26/09/22 | GSK | 07:00:13 | 26 Sept 2022 | | GSK | GSK Chief Financial Officer succession | GSK PLC | RNS |
| 22/09/22 | GSK | 14:00:03 | 22 Sept 2022 | | GSK | US FDA ODAC review of Zejula Phase III NOVA trial | GSK PLC | RNS |
| 22/09/22 | GSK | 07:00:05 | 22 Sept 2022 | | GSK | GSK and Spero Therapeutics licence for tebipenem | GSK PLC | RNS |
| 21/09/22 | GSK | 11:22:18 | 21 Sept 2022 | | GSK | Director/PDMR Shareholding | GSK PLC | RNS |
| 13/09/22 | GSK | 09:11:47 | 13 Sept 2022 | | GSK | Director/PDMR Shareholding | GSK PLC | RNS |
| 08/09/22 | GSK | 12:58:48 | 8 Sept 2022 | | GSK | Director/PDMR Shareholding | GSK PLC | RNS |
| 06/09/22 | GSK | 13:00:01 | 6 Sept 2022 | | GSK | GSK provides update on FDA review of daprodustat | GSK PLC | RNS |
| 01/09/22 | GSK | 11:48:49 | 1 Sept 2022 | | GSK | Total Voting Rights | GSK PLC | RNS |
| 24/08/22 | GSK | 07:00:06 | 24 Aug 2022 | | GSK | GSK Board changes | GSK PLC | RNS |
| 22/08/22 | GSK | 16:53:58 | 22 Aug 2022 | | GSK | Director/PDMR Shareholding | GSK PLC | RNS |
| 17/08/22 | GSK | 07:00:06 | 17 Aug 2022 | | GSK | FDA New Drug Application File Acceptance for MMB | GSK PLC | RNS |
| 17/08/22 | GSK | 07:00:04 | 17 Aug 2022 | | GSK | Statement: Zantac (ranitidine) litigation update | GSK PLC | RNS |
| 16/08/22 | GSK | 07:06:31 | 16 Aug 2022 | | GSK | GSK completes acquisition of Affinivax, Inc. | GSK PLC | RNS |
| 12/08/22 | GSK | 07:00:04 | 12 Aug 2022 | | GSK | Statement: Zantac (ranitidine) litigation | GSK PLC | RNS |
| 11/08/22 | GSK | 11:51:04 | 11 Aug 2022 | | GSK | Director/PDMR Shareholding | GSK PLC | RNS |
| 10/08/22 | GSK | 16:57:10 | 10 Aug 2022 | | GSK | Director/PDMR Shareholding | GSK PLC | RNS |
| 01/08/22 | GSK | 18:10:39 | 1 Aug 2022 | | GSK | Total Voting Rights | GSK PLC | RNS |
| 01/08/22 | GSK | 13:43:15 | 1 Aug 2022 | | GSK | Director/PDMR Shareholding | GSK PLC | RNS |
| 29/07/22 | GSK | 14:00:05 | 29 Jul 2022 | | GSK | Director/PDMR Shareholding | GSK PLC | RNS |
| 29/07/22 | GSK | 10:00:05 | 29 Jul 2022 | | GSK | GSK Board change | GSK PLC | RNS |
| 28/07/22 | GSK | 13:01:16 | 28 Jul 2022 | | GSK | Director/PDMR Shareholding | GSK PLC | RNS |
| 27/07/22 | GSK | 07:00:12 | 27 Jul 2022 | | GSK | 2nd Quarter Results | GSK PLC | RNS |
| 22/07/22 | GSK | 16:45:27 | 22 Jul 2022 | | GSK | Holding(s) in Company | GSK PLC | RNS |
| 22/07/22 | GSK | 16:17:40 | 22 Jul 2022 | | GSK | Board and Committee Changes | GSK PLC | RNS |
| 19/07/22 | GSK | 07:00:04 | 19 Jul 2022 | | GSK | Completion of GSK Share Consolidation | GSK PLC | RNS |
| 18/07/22 | GSK | 07:00:07 | 18 Jul 2022 | | GSK | Haleon demerger completion and share consolidation | GSK PLC | RNS |
| 12/07/22 | GSK | 09:48:01 | 12 Jul 2022 | | GSK | Director/PDMR Shareholding | GSK PLC | RNS |
| 08/07/22 | GSK | 18:04:23 | 8 Jul 2022 | | GSK | Director/PDMR Shareholding | GSK PLC | RNS |
| 08/07/22 | GSK | 17:30:20 | 8 Jul 2022 | | GSK | Director/PDMR Shareholding | GSK PLC | RNS |
| 08/07/22 | GSK | 15:53:19 | 8 Jul 2022 | | GSK | Director/PDMR Shareholding | GSK PLC | RNS |
| 08/07/22 | GSK | 15:33:23 | 8 Jul 2022 | | GSK | Director/PDMR Shareholding | GSK PLC | RNS |
| 08/07/22 | GSK | 15:10:36 | 8 Jul 2022 | | GSK | Director/PDMR Shareholding | GSK PLC | RNS |
| 06/07/22 | GSK | 16:30:05 | 6 Jul 2022 | | GSK | Result of General Meeting | GSK PLC | RNS |
| 06/07/22 | GSK | 10:11:52 | 6 Jul 2022 | | GSK | Director/PDMR Shareholding | GSK PLC | RNS |
| 05/07/22 | GSK | 12:43:53 | 5 Jul 2022 | | GSK | GSK disclose discontinued operations from Q2 2022 | GSK PLC | RNS |
| 05/07/22 | GSK | 09:45:20 | 5 Jul 2022 | | GSK | Director/PDMR Shareholding | GSK PLC | RNS |
| 05/07/22 | GSK | 09:30:18 | 5 Jul 2022 | | GSK | Director/PDMR Shareholding | GSK PLC | RNS |
| 01/07/22 | GSK | 15:27:07 | 1 Jul 2022 | | GSK | Total Voting Rights | GSK PLC | RNS |
| 01/07/22 | GSK | 14:45:55 | 1 Jul 2022 | | GSK | GSK completes acquisition of Sierra Oncology | GSK PLC | RNS |
| 28/06/22 | GSK | 17:56:43 | 28 Jun 2022 | | GSK | Director/PDMR Shareholding | GSK PLC | RNS |
